News Releases

Month Year

Email Alerts

May 17, 2005

Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer
May 10, 2005

Insmed Incorporated Reports Financial Results for First Quarter of 2005
May 5, 2005

Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)
Apr 26, 2005

Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance
Apr 20, 2005

Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)
Apr 18, 2005

Patent Infringement Suit Against Insmed Dismissed
Apr 13, 2005

FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
Mar 16, 2005

Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004
Mar 15, 2005

Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16
Mar 15, 2005

Insmed Announces Completion of $35 Million Financing
Mar 10, 2005

FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
Feb 22, 2005

Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims
Feb 16, 2005

Insmed Provides Response to UK Patent Lawsuit
Jan 7, 2005

University of Rochester Awarded $6.5 Million to Study Efficacy OF rhIGF-I/rhIGFBP-3, SomatoKine, in the Treatment of Myotonic Dystrophy
Jan 3, 2005

Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
Dec 31, 2004

Insmed Completes New Drug Application -NDA- for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome; Conference Call Scheduled for 11:00 am January 5, 2005
Dec 30, 2004

Insmed Incorporated Released the Following Statement in Response to Recent Actions by Tercica, Inc.
Dec 21, 2004

Insmed Incorporated Released the Following Statement in Response to a Press Release Made Yesterday by Tercica, Inc.
Nov 9, 2004

Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine
Nov 8, 2004

Insmed Raises Approximately $8.7 Million in Direct Placement of Common Stock
Nov 8, 2004

Insmed Incorporated Reports Financial Results for Third Quarter and First Nine-Months of 2004
Oct 26, 2004

Insmed to Present at Rodman and Renshaw Healthcare Conference October 28, 2004; Presentation to Be Webcast Live
Oct 21, 2004

Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories
Oct 19, 2004

Insmed Announces Initiation of Clinical Study of Small Molecule IGF-IR Tyrosine Kinase Inhibitor
Sep 13, 2004

Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European Society of Pediatric Endocrinology
Sep 8, 2004

Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Protein
Aug 17, 2004

Insmed Requests Halt of Trading of Its Common Stock on the Berlin-Bremen Stock Exchange; Company Also Initiates Short Selling Audit
Jul 28, 2004

Insmed Incorporated Reports Financial Results for Second Quarter and First Half of 2004
Jul 21, 2004

Insmed to Report Second Quarter Financial Results;Wednesday, July 28
Jul 20, 2004

Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months
Jul 19, 2004

Insmed Receives Authorization for Reimbursement for SomatoKine Named Patient Program from France and Italy; Newly Appointed Chief Business Officer Expands the Named Patient Program
Jul 19, 2004

Insmed Announces Two Independent Presentations at the National Cancer Institutes 12th Annual Meeting of SPORE
May 13, 2004

Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials
May 11, 2004

Insmed to Present at Rodman and Renshaw Healthcare Conference May 13, 2004; Presentation to Be Webcast Live
May 5, 2004

Insmed Incorporated Reports Financial Results for First Quarter of 2004
Apr 29, 2004

Insmed Incorporated to Webcast First Quarter Earnings Conference Call; Thursday, May 6, at 11:00 a.m. ET - 10:00 a.m. CT
Apr 14, 2004

Insmed Acquires Manufacturing Facility from Baxter International
Mar 23, 2004

Insmed to Present at Wells Fargo Securities Healthcare Conference
Mar 23, 2004

Insmed to Present at Wells Fargo Securities Healthcare Conference; Presentation to Be Webcast Live
Feb 11, 2004

Insmed Incorporated Reports Improved Financial Results for Fourth Quarter 2003 and Twelve-Months Ended December 31, 2003
Feb 4, 2004

Insmed Inc. to Webcast Fourth Quarter Earnings Conference Call; Wednesday, February 11, at 11:00 a.m. ET - 10:00 a.m. CT
Jan 26, 2004

Insmed Obtains Patent Rights for Extreme Insulin Resistance From Fujisawa
Dec 15, 2003

Insmed Receives FDA Orphan Drug Designation For rhIGF-I/rhIGFBP-3, SomatoKine, for Extreme Insulin Resistance
Dec 3, 2003

Insmed Presents Positive Data on Anti-Cancer Drug Candidate to San Antonio Breast Cancer Symposium
Dec 2, 2003

rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes

rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes
Nov 17, 2003

Insmed Presents Positive Data on Anti-Cancer Drug Candidate to AACR-NCI-EORTC
Nov 5, 2003

Insmed to Present Cancer Data to CaP Cure, the Prostate Cancer Foundation
Nov 5, 2003

Insmed Incorporated Reports Financial Results for Third Quarter 2003 and Nine-Months Ended September 30, 2003
Oct 28, 2003

Insmed Incorporated to Webcast Third Quarter Earnings Conference Call; Wednesday, November 5, at 11:00 a.m. ET - 10:00 a.m. CT
Oct 16, 2003

Insmed to Present to Rodman and Renshaw Healthcare Conference; Presentation to be Webcast Live

Insmed to Present to Rodman and Renshaw Healthcare Conference; Presentation to be Webcast Live

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer